PVLA
NASDAQ · Biotechnology
Palvella Therapeutics Inc
$116.23
-0.81 (-0.69%)
Open$115.00
Previous Close$117.04
Day High$118.64
Day Low$113.00
52W High$114.69
52W Low$17.31
Volume—
Avg Volume292.5K
Market Cap974.50M
P/E Ratio—
EPS$-3.83
SectorBiotechnology
Analyst Ratings
Strong Buy
22 analysts
Price Target
-54.6% upside
Current
$116.23
$116.23
Target
$52.81
$52.81
$42.56
$52.81 avg
$76.13
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 451.55M | 398.05M | 158.95M |
| Net Income | -90,541,037 | -71,832,628 | 26.26M |
| Profit Margin | -57.3% | -54.5% | 16.5% |
| EBITDA | -90,541,037 | -75,823,329 | 46.23M |
| Free Cash Flow | — | — | 10.92M |
| Rev Growth | +13.4% | +13.4% | +20.5% |
| Debt/Equity | 0.19 | 0.19 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |